Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen. We show 36 historical shares outstanding datapoints in our BLCM shares outstanding history coverage, used to compute BLCM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLCM market cap history over the course of time is important for investors
interested in comparing BLCM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLCM versus a peer is one thing; comparing
BLCM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLCM can fluctuate over the course of history.
With this page we aim to empower investors researching BLCM by allowing them to research the BLCM market cap history. |
Free BLCM Email Alerts:
Video: The Importance of Market Cap
